RE: Results25 Jan 2022 07:31
Market surveillance department.
Another smart move , clearly shows that government are consistently moving goalposts regarding testing policies and company won’t be wasting money developing and researching tests /equipment unless they know they will be financially protected .
“In addition, an international scientific advisory board, and in-country and therapeutic area advisory boards, are being established to assist with market surveillance and direction of future innovation. This is crucial as clinical development, regulatory hurdles, associated costs, and timelines have increased meaning it is important the Company is confident in future value creation before embarking on significant investment in development programmes. In the interim, Novacyt continues to build a strong pipeline of business development opportunities for partnership, licensing, and M&A to strengthen the business and accelerate growth.”